The role of high-mobility group box 1 protein in the pathogenesis of autoimmune diseases Reinhard E. VollVilma UrbonaviciuteJoachim R. Kalden Invited Commentary 16 October 2008 Pages: 341 - 342
Is continuous treatment with infliximab superior to treatment upon symptom relapse in ankylosing spondylitis? Neena JamesMazen ElyanMuhammad Asim Khan Clinical trials report 16 October 2008 Pages: 347 - 348
Behçet’s disease: Recent advances in early diagnosis and effective treatment Kenneth T. CalamiaPhaedon G. Kaklamanis OriginalPaper 16 October 2008 Pages: 349 - 355
Spondyloarthritis at the crossroads of imaging, pathology, and structural damage in the era of biologics Heiner AppelJoachim Sieper OriginalPaper 16 October 2008 Pages: 356 - 363
Do bisphosphonates and statins have a role in spondyloarthritis management? Walter P. Maksymowych OriginalPaper 16 October 2008 Pages: 364 - 370
Are spondyloarthropathies as common as rheumatoid arthritis worldwide? A review Nurullah Akkoc ReviewPaper 16 October 2008 Pages: 371 - 378
Tumor necrosis factor inhibitors and infection complications Monica CrawfordJeffrey R. Curtis OriginalPaper 16 October 2008 Pages: 383 - 389
Rheumatoid arthritis and cardiovascular disease Mary Chester M. Wasko OriginalPaper 16 October 2008 Pages: 390 - 397
Current status of gene therapy for rheumatoid arthritis Daniel F. GaddyPaul D. Robbins OriginalPaper 16 October 2008 Pages: 398 - 404
Regulatory T cells in rheumatoid arthritis Sujata SarkarDavid A. Fox OriginalPaper 16 October 2008 Pages: 405 - 412
Inhibiting interleukin-6 in rheumatoid arthritis Ernest Choy OriginalPaper 16 October 2008 Pages: 413 - 417